Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $510,000 Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 6.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 32,265 shares of the biotechnology company’s stock after purchasing an additional 2,089 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Arrowhead Pharmaceuticals were worth $510,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in ARWR. Police & Firemen s Retirement System of New Jersey lifted its holdings in shares of Arrowhead Pharmaceuticals by 7.6% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 27,339 shares of the biotechnology company’s stock worth $432,000 after buying an additional 1,925 shares during the last quarter. Geode Capital Management LLC increased its position in Arrowhead Pharmaceuticals by 1.0% during the second quarter. Geode Capital Management LLC now owns 2,978,505 shares of the biotechnology company’s stock worth $47,067,000 after acquiring an additional 28,193 shares during the period. PNC Financial Services Group Inc. increased its position in Arrowhead Pharmaceuticals by 297.5% during the second quarter. PNC Financial Services Group Inc. now owns 10,598 shares of the biotechnology company’s stock worth $167,000 after acquiring an additional 7,932 shares during the period. Los Angeles Capital Management LLC acquired a new position in Arrowhead Pharmaceuticals during the 2nd quarter valued at $916,000. Finally, Savant Capital LLC bought a new stake in Arrowhead Pharmaceuticals in the 2nd quarter valued at $201,000. 62.61% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on ARWR. Royal Bank Of Canada boosted their price objective on shares of Arrowhead Pharmaceuticals from $45.00 to $52.00 and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 8th. Chardan Capital restated a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, November 19th. The Goldman Sachs Group raised their price objective on Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the stock a “neutral” rating in a research report on Thursday, November 20th. Finally, B. Riley raised Arrowhead Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 11th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.22.

Insider Activity at Arrowhead Pharmaceuticals

In related news, insider James C. Hamilton sold 20,000 shares of the business’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total value of $700,000.00. Following the sale, the insider owned 212,122 shares of the company’s stock, valued at $7,424,270. The trade was a 8.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders sold 50,000 shares of company stock worth $1,525,000. 4.30% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Stock Up 5.7%

Shares of ARWR opened at $46.79 on Wednesday. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.39. The company has a 50-day moving average price of $37.60 and a two-hundred day moving average price of $25.17. The stock has a market cap of $6.47 billion, a price-to-earnings ratio of -36.55 and a beta of 1.27. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $9.57 and a 12 month high of $46.92.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.